

DAFTAR PUSTAKA

1. WHO (2022). Cancer. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/cancer> - Diakses Maret 2024.
2. WHO (2022). Cervical Cancer. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer> - Diakses Maret 2024.
3. CDC (2024). Cervical Cancer Statistics. Centers for Disease Control and Prevention. <https://beta.cdc.gov/cervical-cancer/statistics/index.html> - Diakses Maret 2024.
4. GLOBOCAN (2024). Cancer Today. World Health Organization. https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&group_populations=1&cancers=23&sexes=2&populations=360&multiple_populations=1 - Diakses Maret 2024.
5. S.P. Somashekhar, K.R. A. Management of Early Stage Cervical Cancer. Reviews on Recent Clinical Trials. 2015 Oct 28;10(4):302–308.
6. Chou B, Prasad Venkatesulu B, Coleman RL, Harkenrider M, Small Jr W. Management of stage I and II cervical cancer: a review. International Journal of Gynecologic Cancer. 2022 Mar 7;32(3):216–224.
7. Khoirun Nisa A, P Juswono U, Martono S. Efek Radioterapi Terhadap Produksi Sel Darah Pada Penderita Ca Mammae Dan Ca Cervix.
8. El-Modir A, Fernando I, Winning J, Allen G. The prognostic impact of anemia in cervical cancer patients treated with chemoradiation. International Journal of Gynecologic Cancer. 2022 Oct 20;A39.3-A40.
9. Wassie M, Aemro A, Fentie B. Prevalence and associated factors of baseline anemia among cervical cancer patients in Tikur Anbesa Specialized Hospital, Ethiopia. BMC Womens Health. 2021 Dec 25;21(1):36.
10. Hidayati AO, Arifah S. Faktor Kejadian Anemia pada Pasien Kanker yang Mendapat Radioterapi dan atau Kemoterapi. Jurnal Kesehatan. 2020 Apr 24;11(1):1-8.
11. Pribadi SY, Yulastuti F, Hapsari WS. Literature Review Analysis of the Side Effects of Chemotherapy in Cervical Cancer Patients in Southeast Asia. Urecol Journal Part G: Multidisciplinary Research. 2022 Aug;2(2):93-107.

12. Pratiwi SE, Trianto HF, Fatinah NN, Ilmiawan MI, Fitrianingrum I, Lestari D. The Profile of Cervical Cancer Patients at Soedarso Hospital. Indonesian Journal of Cancer. 2022 Apr 1;16(1):33.
13. Wicaksono RRB, Wiratno. Efek Radioterapi Terhadap Jumlah Leukosit dan Kadar Hemoglobin Pada Penderita Karsinoma Nasofaring. 2006.
14. Suryaningsih R, Muharini A, Darmawati. Analisis Pengaruh Usia Terhadap Penurunan Kadar Hemoglobin Akibat Dosis Radiasi 2000 cGy pada Kasus Terapi Ca Nasopharynx dan Ca Cervix Menggunakan Radiasi Eksternal di RSUP dr. Sardjito. Teknofisika. 2014 Mei;3(2):1-4.
15. Li B, Shou Y, Zhu H. Predictive value of hemoglobin, platelets, and D-dimer for the survival of patients with stage IA1 to IIA2 cervical cancer: a retrospective study. Journal of International Medical Research. 2021 Dec 23;49(12):030006052110610.
16. Alghamdi AH, Niyaz RI, Al-Jifree H, Khan MA, Alsalmi L. Prevalence of Anemia Among Gynecologic Cancer Patients Who Received Chemotherapy, Radiotherapy, or a Combination of Both at King Abdulaziz Medical City, Jeddah. Cureus. 2021 Aug 31;13(8):e17613.
17. Koulis TA, Kornaga EN, Banerjee R, Phan T, Ghatage P, Magliocco AM, et al. Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study. Clinical and Translational Radiation Oncology. 2017 Jun 1;4:51–56.
18. Ulfa LH, Andriansyah A, Iskandar A. Hubungan Kadar Hemoglobin Sebelum dan Selama Terapi Radiasi dengan Respon Tumor pada Pasien Kanker Serviks di RSUD Abdul Wahab Sjahranie Samarinda. Jurnal Sains dan Kesehatan. 2021 Dec 31;3(6):786–794.
19. Kunos CA, Fabian D, Fredericks T, Baldwin L, Dietrich C, Miller RW, et al. Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer. Frontiers in Oncology. 2023 Jul 6;13.
20. Division of Cancer Prevention and Control (2023). Basic Information About Cervical Cancer. Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/cervical/basic_info/index.htm - Diakses Maret 2024.
21. C N. Clinical Outcomes of Women who attend the Cameroon Baptist Convention Health Services (CBCHS) with Cervical Cancer. Biomedical Journal of Scientific & Technical Research. 2023 Mar 7;49(1):40328-40337.

22. J  ray B, Schaff Z. The pathology of cervical cancer - molecular tests. 2022 Dec 31;66:271–278.
23. American Cancer Society (2023). What Is Cervical Cancer?. American Cancer Society. <https://www.cancer.org/cancer/types/cervical-cancer/about/what-is-cervical-cancer.html> - Diakses Maret 2024.
24. American Cancer Society (2024). Key Statistics for Cervical Cancer. American Cancer Society. <https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html> - Diakses Maret 2024.
25. Kurnia I, Rauf S, Hatta M, Arifuddin S, Hidayat YM, Natzir R, et al. Molecular Patho-mechanisms of cervical cancer (MMP1). *Annals of Medicine & Surgery*. 2022 May;77:103415.
26. Hatib A, Boussettine R, Hassou N, Ennaji MM. Etiology of human papillomavirus in cervical cancer and infection mechanism. In: *Oncogenic Viruses*. Elsevier; 2023. p. 373–386.
27. American Cancer Society (2020). What Causes Cervical Cancer?. American Cancer Society. <https://www.cancer.org/cancer/types/cervical-cancer/causes-risks-prevention/what-causes.html> - Diakses Maret 2024.
28. Prawirohardjo S, Wiknjosastro H. Ilmu Kandungan. 3rd ed. Anwar M, Baziad A, Prabowo P, editors. Jakarta: PT Bina Pustaka Sarwono Prawirohardjo; 2011.
29. Yoon CH, Rho SB, Kim ST, Kho S, Park J, Jang IS, et al. Crucial Role of TSC-22 in Preventing the Proteasomal Degradation of p53 in Cervical Cancer. *PLoS One*. 2012 Aug 1;7(8):e42006.
30. Cullati S, Charvet-B  rard AI, Perneger T V. Cancer screening in a middle-aged general population: factors associated with practices and attitudes. *BMC Public Health*. 2009 Dec 29;9(1):118.
31. Suh Y, Amelio I, Guerrero Urbano T, Tavassoli M. Clinical update on cancer: molecular oncology of head and neck cancer. *Cell Death & Disease*. 2014 Jan 23;5(1):e1018.
32. de Freitas AC, Gurgel APAD, Chagas BS, Coimbra EC, do Amaral CMM. Susceptibility to cervical cancer: An overview. *Gynecologic Oncology*. 2012 Aug;126(2):304–311.
33. Feller L, Khammissa RA, Wood NH, Lemmer J. Epithelial maturation and molecular biology of oral HPV. *Infect Agents and Cancer*. 2009 Dec 25;4(1):16.

34. Faridi R, Zahra A, Khan K, Idrees M. Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. *Virology Journal*. 2011 Dec 3;8(1):269.
35. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. *The Lancet*. 2007 Sep;370(9590):890–907.
36. Stanley M. Pathology and epidemiology of HPV infection in females. *Gynecologic Oncology*. 2010 May;117(2):S5–S10.
37. Meijer CJLM, Snijders PJF, Van Den Brule AJC. Screening for cervical cancer: Should we test for infection with high-risk HPV? Commentary Commentaire. *CMAJ* • SEPT. 2000;5(5).
38. Aziz MF. Gynecological cancer in Indonesia. *Journal of Gynecologic Oncology*. 2009;20(1):8.
39. Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G. Risk factors for Human Papillomavirus Exposure and Co-factors for Cervical Cancer in Latin America and the Caribbean. *Vaccine*. 2008 Aug;26:L16–L36.
40. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy. *Journal of the National Cancer Institute*. 2005 Mar 16;97(6):425–432.
41. Mazumder S, DuPree E, Almasan A. A Dual Role of Cyclin E in Cell Proliferation and Apoptosis May Provide a Target for Cancer Therapy. *Current Cancer Drug Targets*. 2004 Feb 1;4(1):65–75.
42. Division of Cancer Prevention and Control (2023). What Are the Risk Factors for Cervical Cancer?. Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/cervical/basic_info/risk_factors.htm - Diakses Maret 2024.
43. American Cancer Society (2020). Risk Factors for Cervical Cancer. American Cancer Society. <https://www.cancer.org/cancer/types/cervical-cancer/causes-risks-prevention/risk-factors.html> - Diakses Maret 2024.
44. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. *The Lancet Oncology*. 2009 Dec;10(12):1152–1159.

45. Division of Cancer Prevention and Control (2023). What Are the Symptoms of Cervical Cancer?. Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/cervical/basic_info/symptoms.htm - Diakses Maret 2024.
46. American Cancer Society (2020). Signs and Symptoms of Cervical Cancer. American Cancer Society. <https://www.cancer.org/cancer/types/cervical-cancer/detection-diagnosis-staging/signs-symptoms.html> - Diakses Maret 2024.
47. Wu W, Zhou H. Data-Driven Diagnosis of Cervical Cancer With Support Vector Machine-Based Approaches. Institute of Electrical and Electronics Engineers. 2017;5:25189–25195.
48. Bestel M, Erdem B, Bestel A, Karaaslan O. Agreement Between Endocervical Brush and Endocervical Curettage for the Diagnosis of Cervical Cancer. Eastern Journal Of Medicine. 2019;24(1):86–90.
49. American Cancer Society (2020). Tests for Cervical Cancer. American Cancer Society. <https://www.cancer.org/cancer/types/cervical-cancer/detection-diagnosis-staging/how-diagnosed.html> - Diakses Maret 2024.
50. American Cancer Society (2020). Cervical Cancer Stages. American Cancer Society. <https://www.cancer.org/cancer/types/cervical-cancer/detection-diagnosis-staging/staged.html> - Diakses Maret 2024.
51. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. International Journal of Gynecology & Obstetrics. 2021 Oct 20;155(S1):28–44.
52. Canepa M, Patel NR, Garcia-Moliner ML. Pathology and Molecular Diagnosis of Cervical Cancer and Precursor Lesions. In: Uterine Cervical Cancer. Cham: Springer International Publishing; 2019. p. 61–87.
53. Hasugian SA, Lubis K, Doan H V. Profile Of Histopathology Of Cervical Cancer Tissues in Patients Of The Dr Pirngadi Medan Hospital. Jurnal Biosains. 2020 Dec 10;6(3):90.
54. Abbasi MK, Ali N, Naz S, Naval AT, Ali M. Prognostic Value of Histopathology and Trends in Cervical Cancer. Pakistan Journal of Medical and Health Sciences. 2022 Dec 31;16(12):375–377.
55. Guimarães YM, Godoy LR, Longatto-Filho A, Reis R dos. Management of Early-Stage Cervical Cancer: A Literature Review. Cancers (Basel). 2022 Jan 24;14(3):575.

56. Birus H. Different radical surgical treatment of cervical cancer based on the histopathological characteristics of the tumour. *Semmelweis University*. 2022 Dec 31;66(4):289–293.
57. Lintner B. Different radical surgical treatment of cervical cancer based on the histopathological characteristics of the tumour. *Magyar Onkologia*. 2022 Dec 31;66(4):289–293.
58. Zhao H, He Y, Yang SL, Zhao Q, Wu YM. Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis. *Onco Targets and Therapy*. 2019 Mar;12:1881–1891.
59. Chargari C, Peignaux K, Escande A, Renard S, Lafond C, Petit A, et al. Radiotherapy of cervical cancer. *Cancer/Radiothérapie*. 2022 Feb;26(1–2):298–308.
60. Chino J, Annunziata CM, Beriwal S, Bradfield L, Erickson BA, Fields EC, et al. Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*. 2020 Jul;10(4):220–234.
61. Harun HM, Jannah N, Ahmad ZF. Evaluasi Pengobatan Radioterapi Pada Pasien Kanker. *Journal Syifa Sciences and Clinical Research*. 2022;4(3):662-670.
62. de Azevedo CRAS, Thuler LCS, de Mello MJG, de Oliveira Lima JT, da Fonte ALF, Fontão DFS, et al. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. *Gynecologic Oncology*. 2017 Sep;146(3):560–565.
63. Robova H, Rob L, Halaska MJ, Pluta M, Skapa P, Strnad P, et al. High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer. *Gynecologic Oncology*. 2013 Jan;128(1):49–53.
64. Zhao M, Gao Z, Gu X, Yang X, Wang S, Fu J. Predictive significance of lymphocyte level and neutrophil-to-lymphocyte ratio values during radiotherapy in cervical cancer treatment. *Cancer Medicine*. 2023 Aug 16;12(15):15820–15830.
65. Davis T, Krivacsy S, Viswanathan S, English KK, Xie X, Anastos K, et al. Radiotherapy Access and Treatment in Rwanda: Demographics and Clinical Characteristics of Cervical Cancer Patients. *International Journal of Radiation Oncology Biology Physics*. 2023 Oct;117(2):S127.

66. Zheng Z, Hu K, Hou X, Yu L, Yan J, Zhang F. Radiotherapy for postoperative vaginal recurrences of cervical squamous cell carcinoma: analysis of dosing and prognosis. *Journal of Obstetrics and Gynaecology (Lahore)*. 2023 Dec 8;43(2).
67. Zhao M, Gao Z, Gu X, Yang X, Wang S, Fu J. Predictive significance of lymphocyte level and neutrophil-to-lymphocyte ratio values during radiotherapy in cervical cancer treatment. *Cancer Medicine*. 2023 Aug 16;12(15):15820–15830.
68. Feyisa JD, Woldegeorgis MA, Zingeta GT, Abegaz KH, Berhane Y. Cervical Cancer Progression in Patients Waiting for Radiotherapy Treatment at a Referral Center in Ethiopia: A Longitudinal Study. *JCO Glob Oncol*. 2023 May;(9).
69. Zheng Z, Hu K, Hou X, Yu L, Yan J, Zhang F. Radiotherapy for postoperative vaginal recurrences of cervical squamous cell carcinoma: analysis of dosing and prognosis. *Journal of Obstetrics and Gynaecology (Lahore)*. 2023 Dec 8;43(2).
70. Liang C, Xu Z, Yang G, Lv J, Shen X, Wu K. Peripheral Blood Inflammation Indicators as Predictive Factors for Treatment Response Assessed by MRI in Cervical Cancer Patients Referred for Radiotherapy. *Clinical and Experimental Obstetrics & Gynecology*. 2023 Mar 10;50(3):53.
71. National Cancer Institute (2023). Cervical Cancer Treatment. National Institutes of Health. https://www.cancer.gov/types/cervical/treatment#_26 – Diakses Maret 2024.
72. Biete A, Rovirosa A, Osés G. Intraoperative Radiation Therapy in Gynecological Cancer. In: *Gynaecological Malignancies - Updates and Advances*. IntechOpen; 2020.
73. Suryani S, Mirfaiddin, Abdullah B, Rahmat R. Analysis of Skin Radiation Injury After External Curative and Palliative Radiotherapy of Cervix Cancer with Linac. *Gravitasi*. 2022 Dec 23;21(1):30–34.
74. Cozzi L, Beriwal S, Kuusela E, Chopra S, Burger H, Joubert N, et al. A novel external beam radiotherapy method for cervical cancer patients using virtual straight or bending boost areas; an in-silico feasibility study. *Radiation Oncology*. 2021 Dec 14;16(1):110.
75. Campitelli M, Lazzari R, Piccolo F, Ferrazza P, Marsella AR, Macchia G, et al. Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review. *International Journal of Gynecologic Cancer*. 2021 Sep;31(9):1278–1286.

76. Wibowo A, Laihad BJ, Mongan SP, Napitupulu E. Response of External Radiotherapy Alone in Stage IIB – IIIC Cervical Cancer Patients. *Indonesian Journal of Obstetrics and Gynecology*. 2022 Jul 31;145–150.
77. National Cancer Institute (2022). Radiation Therapy Side Effects. National Cancer Institute. <https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/side-effects> - Diakses April 2024.
78. Cho O, Chun M, Oh YT, Noh OK, Chang SJ, Ryu HS, et al. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma. *Tumor Biology*. 2017 Oct 1;39(10):1–9.
79. Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G, et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. *BMC Cancer*. 2007 Dec 23;7(1):164.
80. Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. *Cancer*. 2003 May 17;97(9):2196–2202.
81. Kodaira T, Fuwa N, Nakanishi T, Kuzuya K, Sasaoka M, Tachibana H, et al. Long-Term Clinical Outcomes of Postoperative Pelvic Radiotherapy With or Without Prophylactic Paraaortic Irradiation for Stage I-II Cervical Carcinoma With Positive Lymph Nodes. *American Journal of Clinical Oncology*. 2004 Apr;27(2):140–8.
82. Chang H, Wang M, Liu Y, Wu Y. Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer. *Journal of Gynecologic Oncology*. 2023;34(4).
83. Kim MK, Kim JW, Kim MA, Kim HS, Chung HH, Park NH, et al. Feasibility of less radical surgery for superficially invasive carcinoma of the cervix. *Gynecologic Oncology*. 2010 Nov;119(2):187–191.
84. Pol FJM, Zusterzeel PLM, van Ham MAPC, Kuijpers DAT, Bulten J, Massuger LFAG. Satellite lymphovascular space invasion: An independent risk factor in early stage cervical cancer. *Gynecologic Oncology*. 2015 Sep;138(3):579–584.
85. Huang Y, Wen W, Li X, Xu D, Liu L. Prognostic value of lymphovascular space invasion in stage IA to IIB cervical cancer: A meta-analysis. *Medicine*. 2023 Apr 14;102(15):e33547.

86. Salib MY, Russell JHB, Stewart VR, Sudderuddin SA, Barwick TD, Rockall AG, et al. 2018 FIGO Staging Classification for Cervical Cancer: Added Benefits of Imaging. *RadioGraphics*. 2020 Oct;40(6):1807–1822.
87. Alonso-Espías M, Gorostidi M, Gracia M, García-Pineda V, Diestro MD, Siegrist J, et al. Role of Adjuvant Radiotherapy in Patients with Cervical Cancer Undergoing Radical Hysterectomy. *Journal of Personalized Medicine*. 2023 Oct 12;13(10):1486.
88. Uno T, Ito H, Itami J, Yasuda S, Isobe K, Hara R, et al. Postoperative radiation therapy for stage IB-IIIB carcinoma of the cervix with poor prognostic factors. *Europe PMC*. 2000 May 1;2235–2239.
89. Kato T, Watari H, Takeda M, Hosaka M, Mitamura T, Kobayashi N, et al. Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy. *Journal of Gynecologic Oncology*. 2013;24(3):222.
90. Lin SM, Ku HY, Chang TC, Liu TW, Hong JH. The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study. *Oncotarget*. 2017 Oct 17;8(49):85203–85213.
91. Hong JC, Foote J, Broadwater G, Sosa JA, Gaillard S, Havrilesky LJ, et al. Data-Derived Treatment Duration Goal for Cervical Cancer: Should 8 Weeks Remain the Target in the Era of Concurrent Chemoradiation? *JCO Clinical Cancer Informatics*. 2017 Nov;(1):1–15.
92. Guo J, Lv W, Wang Z, Shang Y, Yang F, Zhang X, et al. Prognostic Value of Inflammatory and Nutritional Markers for Patients With Early-Stage Poorly-to Moderately-Differentiated Cervical Squamous Cell Carcinoma. *Cancer Control*. 2023 Jan 4;30.
93. Niu Z, Yan B. Prognostic and clinicopathological effect of the prognostic nutritional index (PNI) in patients with cervical cancer: a meta-analysis. *Annals of Medicine*. 2023 Dec 12;55(2).
94. Hong BJ, Kim J, Jeong H, Bok S, Kim YE, Ahn GO. Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy. *Radiation Oncology Journal*. 2016 Dec 31;34(4):239–249.
95. Serkies K, Badzio A, Jassem J. Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy. *Acta Oncologica (Madr)*. 2006 Jan 8;45(6):695–701.

96. Lim A, Sia S. Outcomes of Chemoradiotherapy in Cervical Cancer—The Western Australian Experience. *International Journal of Radiation Oncology Biology Physics*. 2012 Mar;82(4):1431–1438.
97. Ferrandina G, Lucidi A, Paglia A, Corrado G, Macchia G, Tagliaferri L, et al. Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: Impact on outcome and treatment-related complications. *European Journal of Surgical Oncology (EJSO)*. 2012 Mar;38(3):238–244.
98. Shin DW, Nam JH, Kwon YC, Park SY, Bae DS, Park CT, et al. Comorbidity in Disease-Free Survivors of Cervical Cancer Compared with the General Female Population. *Oncology*. 2008;74(3–4):207–215.
99. Gillani SW, Zaghloul HA, Ansari IA, Abdul MIM, Sulaiman SAS, Baig MR, et al. Multivariate Analysis on the Effects of Diabetes and related Clinical Parameters on Cervical Cancer Survival Probability. *Scientific Reports*. 2019 Jan 31;9(1):1084.
100. Shen T, Zhao J, Li W, Wang X, Gao Y, Wang Z, et al. Hypertension and hyperglycaemia are positively correlated with local invasion of early cervical cancer. *Frontiers in Endocrinology (Lausanne)*. 2023 Dec 12;14.
101. Spanos WJ, King A, Keeney E, Wagner R, Slater JM. Age as a prognostic factor in carcinoma of the cervix. *Gynecologic Oncology*. 1989 Oct;35(1):66–68.
102. Li J, Liu G, Luo J, Yan S, Ye P, Wang J, et al. Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study. *Scientific Reports*. 2022 Aug 17;12(1):13994.
103. Zhou H, Li Q, Xu C, Liang H, Wang Y, Duan Y, et al. Prognosis of stage III cervical cancer: a two-way outcome study. *Translational Cancer Research*. 2020 Apr;9(4):2565–2575.
104. Pearcey R, Miao Q, Kong W, Zhang-Salomons J, Mackillop WJ. Impact of Adoption of Chemoradiotherapy on the Outcome of Cervical Cancer in Ontario: Results of a Population-Based Cohort Study. *Journal of Clinical Oncology*. 2007 Jun 10;25(17):2383–2388.
105. Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M, et al. Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer—a Meta-analysis. *Clinical Oncology*. 2002 Jun;14(3):203–212.

106. Dröge LH, von Sivers FF, Schirmer MA, Wolff HA. Conventional 3D conformal radiotherapy and volumetric modulated arc therapy for cervical cancer: Comparison of clinical results with special consideration of the influence of patient- and treatment-related parameters. *Strahlentherapie und Onkologie*. 2021 Jun 3;197(6):520–527.
107. Kombathula SH, Jagadesan P, Sinnatamby M, Menon A, Kannikanti DH, R C, et al. Early Clinical Outcomes in Patients of Carcinoma Cervix Treated With Volumetric Modulated Arc Therapy. *Cureus*. 2023 Oct 10;
108. Chen MF, Chen WC, Lai CH, Hung C hsiung, Liu KC, Cheng YH. Predictive factors of radiation-induced skin toxicity in breast cancer patients. *BMC Cancer*. 2010 Dec 23;10(1):508.
109. Patel FD, Sharma SC, Negi PS, Ghoshal S, Gupta BD. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: A clinical trial. *International Journal of Radiation Oncology Biology Physics*. 1994 Jan;28(2):335–341.
110. Teshitma T, Inoue T, Ikeda H, Murayama S, Yamasaki H, Inoue T, et al. High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of osaka university hospital. *Cancer*. 1993 Oct 15;72(8):2409–2414.
111. Knöös T. QA procedures needed for advanced RT techniques and its impact on treatment outcome. *Journal of Physics: Conference Series*. 2015 Jan 12;573:012001.
112. Hizam DA, Jong WL, Mohd Zin H, Ng KH, Ung NM. Patient-specific quality assurance for IMRT delivery: A multicentre study. *Radiation Physics and Chemistry*. 2023 Aug;209:111008.
113. Wannasin R, Likitdee N, Kelly M, Thinkhamrop K. Survival after Diagnosis of Cervical Cancer Patients at a Tertiary Referral Hospital in Northeast Thailand. *Asian Pacific Journal of Cancer Prevention*. 2023 May 1;24(5):1759–1767.
114. M. Al-Jifree H, Alwazzan A, Aljuaid S, Balubaid W. Effect of Age on Survival in Patients with Cervical Cancer. *Pakistan Journal of Health Sciences*. 2023 Feb 28;134–8.
115. Yadav M, Kumar H, Kumar R, Sharma N, Jakhar S. Survival pattern in cervical cancer patients in North West India: A tertiary care center study. *J Cancer Res Ther*. 2022;18(6):1530.

116. Zubaidah Z, Sitorus RJ, Flora R, Tantrakarnapa K. The three-year survival rate of cervical cancer patients at referral hospital in Southern Sumatra, Indonesia. *Jurnal Berkala Epidemiologi*. 2022 May 30;10(2):121–9.
117. Tabatabaei FS, Saeedian A, Azimi A, Kolahdouzan K, Esmati E, Maddah Safaei A. Evaluation of Survival Rate and Associated Factors in Patients with Cervical Cancer: A Retrospective Cohort Study. *J Res Health Sci*. 2022 Jul 11;22(2):e00552–e00552.
118. Barkati M, Fortin I, Mileschkin L, Bernshaw D, Carrier JF, Narayan K. Hemoglobin Level in Cervical Cancer. *International Journal of Gynecological Cancer*. 2013 May;23(4):724–9.
119. Gennigens C, De Cuyper M, Seidel L, Hermesse J, Barbeaux A, Forget F, et al. Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. *Cancer Med*. 2020 Nov 20;9(22):8432–43.
120. Gede P, Budiarta A, Suega K. Hubungan Kadar Hemoglobin dengan Stadium Kanker Di RSUP Sanglah Denpasar. *Jurnal Medika Udayana*. 2023 Okt;12(10):28-32.
121. Shin NR, Lee YY, Kim SH, Choi CH, Kim TJ, Lee JW, et al. Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. *Obstet Gynecol Sci*. 2014;57(1):28.
122. Castro-Mollo MW, Galvez-Nino M, Ruiz R, Roque K, Coanqui O, Valdivieso N, et al. Impact of hemoglobin on survival of young women with cervical cancer treated with concurrent chemoradiotherapy. *Journal of Clinical Oncology*. 2023 Jun 1;41(16_suppl):e17529–e17529.
123. Anic K, Schmidt MW, Schmidt M, Krajnak S, Löwe A, Linz VC, et al. Impact of perioperative red blood cell transfusion, anemia of cancer and global health status on the prognosis of elderly patients with endometrial and ovarian cancer. *Front Oncol*. 2022 Sep 16;12.
124. Anic K, Schmidt M, Hasenburg A, Battista MJ. 2022-RA-1129-ESGO Anemia of cancer, transfusion rates and frailty status predict survival in women with endometrial cancer. In: *Endometrial cancer*. BMJ Publishing Group Ltd; 2022. p. A136.1-A136.
125. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lopez C, et al. Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer

- Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery. *International Journal of Gynecological Cancer*. 2017 Mar;27(3):514–22.
126. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lopez C, et al. Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery. *International Journal of Gynecological Cancer*. 2017 Mar;27(3):514–22.
127. Schoenfeld DA. Sample-Size Formula for the Proportional-Hazards Regression Model. Vol. 39. 1983.
128. Musa J, Nankat J, Achenbach CJ, Shambe IH, Taiwo BO, Mandong B, et al. Cervical cancer survival in a resource-limited setting-North Central Nigeria. *Infect Agent Cancer*. 2016 Mar 24;11(1).
129. Ahmad OB, Boschi-Pinto C, Lopez Christopher AD, Murray JL, Lozano R, Inoue M. Age Standardization of Rates : A New WHO Standard. World Health Organization. 2001.
130. Indah YK, Handayani H, Hijriyati Y. Correlation Between the Radiation Fractionation Number and the Major Nursing Problems in Cervical Cancer Patients Undergoing External Radiation. *Jurnal Keperawatan Komprehensif (Comprehensive Nursing Journal)*. 2023 Apr 30;9(2).
131. Yuliandari I, Masluroh. Analisis Faktor Risiko Kanker Serviks Pada Pasien Kanker Serviks Di RSUD Kabupaten Bekasi. *Jurnal Keperawatan Muhammadiyah*. 2024;9(3):2024.
132. Lelly E. Faktor Risiko Kanker Serviks Pada Wanita Lanjut Usia Di RSD Gunung Jati Kota Cirebon. *Sekolah Tinggi Ilmu Kesehatan (STIKes) Mahardika*. 2019;
133. Zahira N, Hutapea J, Lina J. Karakteristik Penderita Kanker Serviks di Rumah Sakit Murni Teguh Medan Periode April-Juni Tahun 2024. *Action Research Literate*. 2024;8(10):2791–8.
134. Amin Y, Mulawardhana P, Erawati D. Respon Terapi dan Survival rate Pasien Kanker Serviks Stadium III-IVA yang Mendapat Kemoterapi Dilanjutkan Radioterapi. *Majalah Obstetri & Ginekologi*. 2015 Dec;23(3):97–105.
135. Harta Widjaya G, Kemenkes Semarang P. Teknik Radioterapi Eksternal Kanker Serviks Dengan Separasi Lebih Dari 20 Centimeter Pada Pesawat Teleterapi Cobalt-60 di Unit Radioterapi Instalasi Radiologi RSUP Dr. Kariadi Semarang. *JlmeD*. 2018;4(1):16–21.

136. Davis T, Krivacsy S, Viswanathan S, English KK, Xie X, Anastos K, et al. Radiotherapy Access and Treatment in Rwanda: Demographics and Clinical Characteristics of Cervical Cancer Patients. *International Journal of Radiation Oncology Biology Physics*. 2023 Oct;117(2):S127.
137. Fitriatsani AN. Hubungan Stadium dan Pemberian Tindakan dengan Derajat Anemia Pada Pasien Kanker Serviks di RSUD Abdul Moeloek Tahun 2018-2022. Universitas Negeri Lampung. 2024 Jan 16;
138. Natania Budiharjo K, Yuseran H, Yasmina A, Amanza F, Mashuri M. Perbedaan Kadar MCV Dan MCHC Pada Pasien Kanker Serviks Sebelum Dan Sesudah Kemoterapi. *Homeostasis*. 2023;6(1):183–90.
139. Putra IH. Kesintasan Pasien Kanker Serviks Di RS Dr. Mohammad Hoesin Periode Januari 2021-2023. Universitas Sriwijaya. 2024 Nov 29;
140. Purbadi S, Fadhly RMA. Faktor-faktor yang Berhubungan dengan Kesintasan Pasien Kanker Serviks yang Ditatalaksana dengan Histerektomi Radikal dan Limfadenektomi. Berhubungan dengan Kesintasan Pasien Kanker Serviks eJKI. 2019;7(1).
141. Gayatri D, Besral B, Nurachmah E. Peluang Ketahanan Hidup 5 Tahun Pasien Kanker Serviks Di RSUPN Dr. Cipto Mangunkusumo dan RSK Dharmais, Jakarta, 2002. *Jurnal Keperawatan Indonesia*. 2003 Mar 27;7(1):17–21.
142. Hasankhani MB, Jahani Y, Bazrafshan A, Yazdizadeh A, Karamoozian A. Factors Affecting Survival of Patients with Cervical Cancer. *Iran J Public Health*. 2023 Oct 14;
143. Bahar I, Tjokroprawiro BA, Erawati D. Radiotherapy Response of Advanced Squamous and Adenocarcinoma Types of Cervical Cancer at Dr Soetomo Hospital Surabaya. *Majalah Obstetri & Ginekologi*. 2013 Aug;21(2):48–55.
144. Farma NA, Muhammad S, Asterina A. Hubungan Usia, Hemoglobin, dan Indeks Massa Tubuh dengan Perubahan Ukuran Tumor pada Kemoterapi Neoadjuvant Kanker Serviks Stadium IB2 dan IIA2 di RSUP Dr. M. Djamil Padang. *Jurnal Ilmu Kesehatan Indonesia*. 2021 Jul 30;2(1):62–9.